Scarica l'app Stockscreener
11.33
6.90%
-0.84
Dopo l'orario di chiusura:
11.37
0.04
+0.35%
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com Canada
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
A drug-development expert with 30 years’ experience joins Candel’s board - Stock Titan
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 - Investing.com
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - PR Newswire UK
Candel Therapeutics to Present at September Investor Conferences - The Manila Times
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock - MarketBeat
Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Hits New 1-Year HighHere's Why - MarketBeat
Candel Therapeutics CTO Seshu Tyagarajan Executes 7,000-Share Sale Under 10b5-1 Plan - Kalkine Media
Candel Therapeutics (NASDAQ: CADL) insider plans 7,000-share 10b5-1 sale - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Trading 6.4% Higher Following Analyst Upgrade - MarketBeat
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Weekly Recap: CAN-2409 BLA filing, 2027 U.S. launch target and Q2 widened loss, shares up - TradingView
Research Analysts Set Expectations for CADL Q3 Earnings - MarketBeat
CADL Q3 EPS Estimate Reduced by Brookline Capital Markets - MarketBeat
(CADL) Risk Channels and Responsive Allocation - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $23 - Moomoo
Stifel Nicolaus Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics (CADL) Receives a Hold from Bank of America Securities - The Globe and Mail
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - theglobeandmail.com
Candel Therapeutics (NASDAQ:CADL) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
LifeSci Capital Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss - MarketBeat
Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside - TradingView
BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 - Moomoo
Equities Analysts Offer Predictions for CADL FY2028 Earnings - MarketBeat
A Quick Look at Today's Ratings for Candel Therapeutics(CADL.US), With a Forecast Between $12 to $25 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - theglobeandmail.com
Candel Therapeutics (NASDAQ:CADL) Releases Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics grants stock options to new Chief Commercial Officer - scanx.trade
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - TradingView
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):